Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

  • This share is currently suspended. It was suspended at a price of 0.75
  • There is currently no data for BELL

Directorate Change

22 Sep 2025 07:00

RNS Number : 2184A
Belluscura PLC
22 September 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

22 September 2025

 

 

Belluscura plc

("Belluscura" or the "Company")

 

 

Update regarding Proposed Funding

Board changes

 

 

Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, further to the statement issued on 12 September 2025, discussions with Omaha Value, Inc. and a connected company called AI Ventures, Inc, regarding the proposed fundraising, have not yet been concluded as anticipated. Discussions have continued, however, with Omaha Value, Inc, AI Ventures, Inc and other potential investors with a view to the refinancing of Belluscura and Belluscura LLC, the Company's main trading subsidiary.

 

As a result, Belluscura LLC has taken steps to enable it to meet its immediate cash requirements.  Whilst the senior management team and those employees responsible for Sales and Shipping have been retained, to ensure the continued fulfilment of customer orders, the employment contracts of 15 of Belluscura LLC's 25 employees in the United States have been terminated.

 

Board changes

 

The Company also announces that Bob Rauker remains CEO of Belluscura LLC but has resigned from the board of Belluscura with immediate effect.

 

Ric Piper, who has been a Director of Belluscura since its AIM flotation in 2021, has also resigned as a non-executive director of Belluscura with immediate effect.

 

 

The ongoing funding discussions mean that the Company is still not yet able to finalise the 2024 Annual Report and Accounts and as a result trading in the Company's shares on AIM remains suspended.

 

 

A further announcement will be made in due course.

 

 

For further information please contact:

 

 

Belluscura plc

Tel: +44 (0)20 3128 8100

Paul Tuson, Chairman

 

SPARK Advisory Partners Limited - Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Dillon Wall

Dowgate Capital Limited - Joint Broker

Tel: +44 (0)20 3903 7715

Russell Cook / Daniel Ingram

Allenby Capital Limited - Joint Broker

Tel: +44 (0)20 3328 5656

Guy McDougall / Amrit Nahal (Sales and Corporate Broking)

Jeremy Porter / Lauren Wright (Corporate Finance)

MHP - Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

Katie Hunt / Matthew Taylor

email: Belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPKDBDBBKBFCB
Date   Source Headline
27th Jan 202312:41 pmRNSPlacing of Unsecured Convertible Loan Notes
24th Jan 20234:40 pmRNSSecond Price Monitoring Extn
24th Jan 20234:35 pmRNSPrice Monitoring Extension
16th Jan 20237:00 amRNSBelluscura appoints Senior VP of Global Sales
13th Jan 20237:00 amRNSYear-end Trading Update
11th Jan 20234:40 pmRNSSecond Price Monitoring Extn
11th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Dec 20227:00 amRNSFirst international distribution agreement
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20222:06 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
14th Nov 202211:05 amRNSSecond Price Monitoring Extn
14th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSBelluscura receives certification to ISO standard
31st Oct 20225:46 pmRNSHolding(s) in Company
31st Oct 20225:41 pmRNSDirector/PDMR Shareholding
31st Oct 20225:38 pmRNSDirector/PDMR Shareholding
24th Oct 20227:00 amRNSBelluscura wins two HME Business Awards
23rd Sep 202211:45 amRNSHolding(s) in Company
20th Sep 20227:01 amRNSHalf-year Report
20th Sep 20227:00 amRNSBelluscura signs agreement with US distributor
6th Sep 20227:00 amRNSNotice of Results
18th Aug 20221:25 pmRNSDirector/PDMR Shareholding
10th Aug 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20222:26 pmRNSAgreement with VGM, largest MSO in US-replacement
2nd Aug 202212:53 pmRNSAgreement with VGM, largest DSO in US-replacement
2nd Aug 20227:00 amRNSSupply Agreement with VGA, largest MSO in the US
15th Jul 20227:00 amRNSWarrant Exercise
14th Jul 20227:00 amRNSExercise of Warrants
30th Jun 20227:00 amRNSDirect to Consumer Sales and Distribution Plan
27th Jun 20227:00 amRNSLaunch of Next Gen X-PLOR Oxygen Concentrator
25th May 20221:19 pmRNSTR-1: Notification of major holdings
24th May 20225:27 pmRNSTR-1: Notification of major holdings
19th May 20227:00 amRNSBelluscura Expands its Patent Portfolio
17th May 202212:00 pmRNSApplications Announcement
13th May 202211:00 amRNSResult of Placing
12th May 20225:01 pmRNSProposed placing to raise £5.0m
25th Apr 20221:00 pmRNSResult of AGM
21st Apr 20227:00 amRNSSenior Management Appointment
7th Apr 20227:00 amRNSDAPA Contract
5th Apr 20226:31 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSenior Management Appointment
1st Apr 20227:00 amRNSNotice of AGM and Annual Report 2021
30th Mar 20227:00 amRNSManufacturing Agreement
22nd Feb 20227:00 amRNSFinal Results
27th Jan 202211:06 amRNSSecond Price Monitoring Extn
27th Jan 202211:00 amRNSPrice Monitoring Extension
24th Jan 20227:00 amRNSTrading Update and Notice of Preliminary Results
20th Jan 20222:32 pmRNSExercise of Warrants and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.